

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Michael Joseph Coghlan	Group Art Unit: 1625
Serial No.: 10/576,901	Examiner: T. Solola
Application Date: December 15, 2004	Conf No.: 5935
US Nat'l Entry Date: April 20, 2006	
For: TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS	
Docket No.: X-16398	

**INTERVIEW SUMMARY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

On May 27, 2008, Examiner Solola and Attorney for the applicants, Alexander Wilson, conducted a telephonic interview to discuss the pending rejection of the claims in United States Patent Application No. 10/576,901. During the conversation, Attorney for the applicants proposed amending Claim 1 in an effort to expedite prosecution of the application. The Examiner asked the Attorney to fax a draft amended Claim 1 to the Examiner for his review and indicated that he would contact the Attorney with any further comments.

On May 29, 2008 the Examiner called the Attorney and indicated that the draft amended Claim 1 would be allowable if (C1-C6)alkoxy were cancelled from the definition of R2. On June 6, 2008 the Attorney left a telephone message for Examiner Solola indicating his agreement to cancel (C1-C6)alkoxy from the definition of R2.

Respectfully submitted,

/Alexander Wilson/

Alexander Wilson  
Attorney for Applicants  
Registration No. 45,782  
Phone: 317-277-0190

Serial No. 10/576,901

Eli Lilly and Company  
Patent Division/  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

June 17, 2008